Comparison of primary octreotide-lar and surgical treatment in newly diagnosed patients with acromegaly

被引：21

作者：

Karaca, Z. ^{[1
]}

Tanriverdi, F. ^{[1
]}

Elbuken, G. ^{[1
]}

Cakir, I. ^{[1
]}

Donmez, H. ^{[2
]}

Selcuklu, A. ^{[3
]}

Durak, A. C. ^{[2
]}

Dokmetas, H. S. ^{[4
]}

Colak, R. ^{[5
]}

Unluhizarci, K. ^{[1
]}

Kelestimur, F. ^{[1
]}

机构：

[1] Erciyes Univ, Dept Endocrinol, Sch Med, TR-38039 Kayseri, Turkey

[2] Erciyes Univ, Dept Radiol, Sch Med, TR-38039 Kayseri, Turkey

[3] Erciyes Univ, Dept Neurosurg, Sch Med, TR-38039 Kayseri, Turkey

[4] Cumhuriyet Univ, Dept Endocrinol, Sch Med, Sivas, Turkey

[5] Ondokuz Mayis Univ, Dept Endocrinol, Sch Med, Samsun, Turkey

来源：

CLINICAL ENDOCRINOLOGY | 2011年 / 75卷 / 05期

关键词：

ACTING SOMATOSTATIN ANALOG; SECRETING PITUITARY-ADENOMAS; GROWTH-FACTOR-I; LONG-TERM; TUMOR SHRINKAGE; DISEASE-ACTIVITY; MEDICAL THERAPY; HORMONE EXCESS; SURGERY; MULTICENTER;

D O I：

10.1111/j.1365-2265.2011.04106.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective The primary aim of the study was to compare the efficacy of Oct-LAR and surgery in terms of controlling IGF-1 and GH levels and tumour volumes. The second aim was to compare two primary treatment modalities in terms of side effects such as pituitary insufficiency, cholelithiasis, metabolic parameters and the effect on quality of life (QoL). Design The study was a randomized, prospective study. Patients The 22 patients were consecutively randomized to Oct-LAR and surgical treatment groups. Results Baseline serum IGF-1 level, tumour volume and GH levels were comparable in the Oct-LAR and surgery groups. No significant differences were detected between the Oct-LAR and the surgery groups in terms of IGF-1 and GH levels at the 3rd and 6th months, but at 12th month, preglucose GH was found to be lower in the surgical treatment group. IGF-1 control and complete biochemical response rates were found to be 27% and 64%, in the Oct-LAR and surgical treatment groups, respectively. The mean percentage of tumour volume reduction was found to be 26%, 30% and 31% in the Oct-LAR group vs 64%, 74% and 79% in the surgery group at the 3rd, 6th and 12th months, respectively. Conclusion Primary surgical treatment seems to be slightly more effective than Oct-LAR in terms of biochemical response and IGF-1 control, besides tumour volume reduction, in patients with acromegaly with noninvasive tumours. Oct-LAR is associated with more side effects such as cholelithiasis and glucose metabolism disorders and is more expensive.

引用

页码：678 / 684

页数：7

共 38 条

[1] Efficacy of Sandostatin® LAR® (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy [J].